REGN241108P1300000
- 0.00
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Sanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment
Express News | Regeneron - Dupixent (Dupilumab) Approved in European Union as First and Only Medicine for Young Children With Eosinophilic Esophagitis
Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,126
Regeneron Pharmaceuticals Insider Sold Shares Worth $844,610, According to a Recent SEC Filing
Tuesday Market Closed Up, with Presidency in Sight | Wall Street Today
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
We Want YOU to Submit Questions for Election Night
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,110
Monday Market Moves Sideways, Election and FOMC in Sight | Wall Street Today
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Monday Market Mixed Before Crazy, Pivotal Week | Live Stock
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,195
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
TD Cowen Reaffirms Their Buy Rating on Regeneron (REGN)
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $800 to $1,195
Weekly Buzz: Magnificent Mix of Market Reactions
November Starts with a Climb to end Tough Week | Wall Street Today
Regeneron Pharma Price Target Cut to $1126.00/Share From $1137.00 by Truist Securities
Regeneron Pharma Is Maintained at Buy by Truist Securities